Diabetes Mellitus and DPP IV/CD26 Inhibitors

Medicina Fluminensis - Croatia
doi 10.21860/medflum2019_221600
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

University of Rijeka, Faculty of Medicine

Related search

Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

Journal of thee Medical Sciences (Berkala Ilmu Kedokteran)
2016English

Dipeptidyl Peptidase-4 (DPP-4; CD26)

Science-Business eXchange
2014English

Rapid Isolation of Endosomes From BHK Cells: Identification of DPP IV (CD26) in Endosomes

Experimental Cell Research
Cell Biology
1996English

Systematic Literature Review of DPP-4 Inhibitors in Patients With Type 2 Diabetes Mellitus and Renal Impairment

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

Prescription of DPP-4 Inhibitors to Type 2 Diabetes Mellitus Patients With Renal Impairment: A UK Primary Care Experience

Clinical Therapeutics
Pharmacology
2018English

Emerging DPP-4 Inhibitors: Focus on Linagliptin for Type 2 Diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2013English

Clinicians Should Think Twice Before Prescribing DPP-4 Inhibitors for Diabetes

Evidence-Based Medicine
Medicine
2016English

Use of DPP-4 Inhibitors in Type 2 Diabetes: Focus on Sitagliptin

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2010English

Pdb81 - Dapagliflozin Is Cost-Effective Compared to DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy